



Date: 23 August 2019

Sydney, Australia

ASX Limited
20 Bridge Street
SYDNEY NSW 2000

NOX RECEIVES 2018/19 FEDERAL GOVERNMENT R&D TAX REBATE

- Noxopharm receives \$3.71M cash rebate
 - Ongoing high-quality clinical research with local and international scientific partners
 - Focus on rapid time to market
 - Partial pay-down of Convertible Note
-

Sydney, 23 August 2019: Noxopharm Limited (ASX: NOX) is pleased to announce that it has received \$3.71M cash rebate as part of the Federal Government R&D Tax Incentive Scheme.

Greg van Wyk, Noxopharm Chief Executive Officer, said, 'The support we receive from the Australian Government, by way of the R&D rebate scheme, is a key factor in enabling us to conduct high quality research with Australian scientific partners and be able to select partners in other jurisdictions. We are grateful for this support.'

'This year's rebate helps to put the Company in a solid financial position to finish the 2019 calendar year and provide ongoing liquidity for a busy 2020 clinical agenda. Our clinical program next year for Veyonda® is extremely exciting and appropriately ambitious. It is an integrated strategy focused on bringing Veyonda® to market in the shortest time possible, plus maximising its market uptake following approval.'

Under the terms of the recent funding facility entered into by the Company, it also will use \$1.5M from the rebate to reduce its current \$4M convertible note funding facility, bringing that Note back to \$2.5M and with it, a significantly lower dilutionary effect when the Note's 6-month lock matures early-2020.

About Noxopharm

Noxopharm is a clinical-stage Australian drug development company with offices in Sydney and New York. The Company has a primary focus on the development of Veyonda® and is the major shareholder in Nyrada Inc, a spin-off company developing a pipeline of non-oncology drugs.

About Veyonda®

Veyonda® (previously known as NOX66) is a suppository dosage formulation of the experimental anti-cancer drug, idronoxil, that leads in the body to the formation of a proprietary pro-drug form. Idronoxil specifically inhibits the



ability of cancer cells to respond to stress, such as that induced by radiation, leading to loss of pro-survival signaling via sphingosine-1-phosphate. Idronoxil also promotes the STING mechanism, thereby activating the body's innate immune system.

www.noxopharm.com

Investor & Corporate Enquiries:

Prue Kelly
M: 0459 022 445
E: info@noxopharm.com

Company Secretary:

David Franks
T: +61 2 9299 9690
E: David.Franks@automicgroup.com.au

Media Contact USA:

Frank de Maria
Purposeful Communications
T: +1 347 647 0284
E: frank.demaria@purposefulcommunications.com

Media Contact Australia

Marianne Gould
Noxopharm Ltd
T: +61 2 9144 2223
E: Marianne.gould@noxopharm.com

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as "aim", "anticipate", "assume", "believe", "continue", "could", "estimate", "expect", "intend", "may", "plan", "predict", "project", "plan", "should", "target", "will" or "would" or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement. No representation, warranty or assurance (express or implied) is given or made by Noxopharm that the forward-looking statements contained in this announcement are accurate and undue reliance should not be placed upon such statements.